Thermosensitive hydrogel with Aliskrien influence the heart function of rats with acute myocardial infarction

doi:10.3969/j.issn.2095-4344.2014.43.011

Abstract

Abstract:

BACKGROUND: Previous experiments have shown that the thermosensitive hydrogel is safe, nontoxic, biocompatible, and has a certain cardioprotective effect, which can be used as a drug carrier injected into the myocardial tissue, in order to avoid adverse reactions produced by systemic administration.
OBJECTIVE: To observe the influence of thermosensitive hydrogel with Aliskrien on heart function, apoptosis and ventricular remodeling of rats with acute myocardial infarction.
METHODS: Totally 70 Wistar rats were randomized into sham group (n=10), PBS group (n=15), PBS+Aliskrien group (n=15), hydrogel group (n=15), hydrogel+Aliskrien group (n=15). Models of acute myocardial infarction were established in the latter four groups. After modeling, PBS, PBS with Aliskrien, hydrogel, and hydrogel with Aliskrien were respectively injected into the border of infracted myocardium. After 28 days, relevant measurements were performed.
RESULTS AND CONCLUSION: Compared with the sham group, the heart function and expression of tissue inhibitor of metalloproteinase-1 were decreased significantly in the other four groups (P < 0.05), while the number of apoptotic cells, matrix metalloproteinase-2, matrix metalloproteinase-9, transforming growth factor β, collagen type I and III were increased (P < 0.05). The levels of angiotensin I and angiotensin II were higher in the PBS, PBS+Aliskrien, hydrogel groups than the sham group (P < 0.05), while they were decreased in the hydrogel+
Aliskrien group than the sham group (P < 0.05). The level of tissue inhibitor of metalloproteinase-1 and heart function in the hydrogel+Aliskrien group were superior to those in the PBS, PBS+Aliskrien, and hydrogel groups (P < 0.05), while the number of apoptotic cells, the levels of metalloproteinase-2, matrix metalloproteinase-9, transforming growth factor β, collagen type I and III were lower than those in the PBS, PBS+Aliskrien, and hydrogel groups (P < 0.05). These findings indicate that as a new type of sustained-release formulation, thermosensitive hydroge with Aliskrien could further improve the heart function, decrease cell apoptosis and inhibit myocardial fibrosis, and delay ventricular remodeling after myocardial infarction.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

全文链接：

Key words: hydrogel, myocardial infarction, apoptosis

CLC Number:

R318

Chen Pan-pan, Li Xiao-yan, Jiang Xue-jun, Liu Yang. Thermosensitive hydrogel with Aliskrien influence the heart function of rats with acute myocardial infarction[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(43): 6951-6958.

Figures/Tables 6

References

[1] van der Linde D,Konings EE,Slager MA,et al.Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis.J Am Coll Cardiol. 2011;58(21):2241-2247.
[2] Abbate A,Biondi-Zoccai GG,Baldi A.Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol. 2002;193(2):145-153.
[3] Cohn JN,Ferrari R,Sharpe N.Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.J Am Coll Cardiol. 2000;35(3):569-582.
[4] Kloner RA,Rezkalla SH.Cardiac protection during acute myocardial infarction: where do we stand in 2004?J Am Coll Cardiol.2004;44(2):276-286.
[5] Savoia C,Volpe M.Angiotensin receptor modulation and cardiovascular remodeling. J Renin Angiotensin Aldosterone Syst.2011;12(3):381-284.
[6] Ferrario CM.Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.Am J Cardiol.2006;98(1):121-128.
[7] Mentz RJ,Bakris GL,Waeber B,et al.The past,present and future of renin-angiotensin aldosterone system inhibition.Int J Cardiol. 2013;167(5):1677-1687.
[8] Vijayaraghavan K,Deedwania P. Renin-angiotensin- aldosterone blockade for cardiovascular disease prevention. Cardiol Clin.2011;29(1):137-156.
[9] Cohn JN.Reducing cardiovascular risk by blockade of the renin-angiotensin- aldosterone system.Adv Ther. 2007;24(6): 1290-304.
[10] Horký K.Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?Vnitr Lek.2007;53(4):364-370.
[11] Van Tassell BW,Munger MA.Aliskiren for renin inhibition: a new class of antihypertensives.Ann Pharmacother. 2007; 41(3):456-464.
[12] Volpe M,Battistoni A,Chin D,et al.Renin as a biomarker of cardiovascular disease in clinical practice.Nutr Metab Cardiovasc Dis.2012;22(4):312-317.
[13] 罗芳.生物医用水凝胶材料的研究进展[J].广东化工,2011,38(8): 104-105.
[14] Wu DQ,Wang T,Lu B,et al.Fabrication of Supramolecular Hydrogels for Drug Delivery and Stem Cell Encapsulation. Langmuir.2008;24(18):10306-10312.
[15] McMurray JJ,Adamopoulos S,Anker SD,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-1847.
[16] Gallagher GL,Jackson CJ,Hunyor SN.Myocardial extracellular matrix remodeling in ischemic heart failure.Front Biosci.2007;12:1410-1419.
[17] Jiang XJ,Wang T,Li XY,et al.Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction.J Biomed Mater Res A.2009;90(2):472-477.
[18] Riccioni G.Aliskiren in the treatment of hypertension and organ damage.Cardiovasc Ther.2011;29(1):77-87．
[19] Abramov D,Carson PE.The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.J Renin Angiotensin Aldosterone Syst. 2012;13(3):317-327.
[20] McMurray JJ,Pitt B,Latini R,et al.Aliskiren Observation of Heart Failure Treatment(ALOFT)Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.Circ Heart Fail.2008;1(1):17-24.
[21] Pilz B,Shagdarsuren E,Wellner M,et al.Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.Hypertension. 2005;46(3):569-576.
[22] Puig JG,Schunkert H,Taylor AA,et al.Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.Clin Ther. 2009;31(12): 2839-2850.